Telix Financial Statements From 2010 to 2024
| TLPPF Stock | USD 14.56 0.50 3.56% |
Check Telix Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telix Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Telix financial statements analysis is a perfect complement when working with Telix Pharmaceuticals Valuation or Volatility modules.
Telix |
Telix Pharmaceuticals Limited Company Return On Equity Analysis
Telix Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Telix Pharmaceuticals Return On Equity | -1.55 |
Most of Telix Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telix Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Telix Pharmaceuticals Limited has a Return On Equity of -1.5507. This is 93.53% lower than that of the Healthcare sector and 95.75% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Telix Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Telix Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Telix Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telix Pharmaceuticals competition to find correlations between indicators driving Telix Pharmaceuticals's intrinsic value. More Info.Telix Pharmaceuticals Limited is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telix Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Telix Pharmaceuticals Financial Statements
Telix Pharmaceuticals stakeholders use historical fundamental indicators, such as Telix Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Telix Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Telix Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Telix Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Telix Pharmaceuticals Limited. Please read more on our technical analysis and fundamental analysis pages.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Telix Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out the analysis of Telix Pharmaceuticals Correlation against competitors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.